Cargando…

Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac

A novel therapeutic vaccine for chronic hepatitis B (CHB) treatment comprising the recombinant hepatitis B surface (HBsAg) and nucleocapsid (HBcAg) antigens has been developed. Preclinical and clinical trials (CT) evidenced safety and immunogenicity in animal models as well as in phases I, II, and I...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Guillermo, L Sanchez, Ana, Jerez, Everardo, E Anillo, Luis, Freyre, Freya, A Aguiar, Jorge, Leon, Yamila, Cinza, Zurina, A Diaz, Pablo, Figueroa, Nelvis, Muzio, Verena, G Nieto, Gerardo, Lobaina, Yadira, Aguilar, Arístides, Penton, Eduardo, C Aguilar, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395482/
https://www.ncbi.nlm.nih.gov/pubmed/30828555
http://dx.doi.org/10.5005/jp-journals-10018-1279
_version_ 1783399098419773440
author Fernández, Guillermo
L Sanchez, Ana
Jerez, Everardo
E Anillo, Luis
Freyre, Freya
A Aguiar, Jorge
Leon, Yamila
Cinza, Zurina
A Diaz, Pablo
Figueroa, Nelvis
Muzio, Verena
G Nieto, Gerardo
Lobaina, Yadira
Aguilar, Arístides
Penton, Eduardo
C Aguilar, Julio
author_facet Fernández, Guillermo
L Sanchez, Ana
Jerez, Everardo
E Anillo, Luis
Freyre, Freya
A Aguiar, Jorge
Leon, Yamila
Cinza, Zurina
A Diaz, Pablo
Figueroa, Nelvis
Muzio, Verena
G Nieto, Gerardo
Lobaina, Yadira
Aguilar, Arístides
Penton, Eduardo
C Aguilar, Julio
author_sort Fernández, Guillermo
collection PubMed
description A novel therapeutic vaccine for chronic hepatitis B (CHB) treatment comprising the recombinant hepatitis B surface (HBsAg) and nucleocapsid (HBcAg) antigens has been developed. Preclinical and clinical trials (CT) evidenced safety and immunogenicity in animal models as well as in phases I, II, and III clinical trials. A phase I CT has conducted in Cuba in 6 CHB patients refractory or incomplete responders to α-IFN. Patients were immunized ten times every two weeks via. nasal spray, with 100 ug HBsAg and 100 ug HBcAg. Clinical efficacy was monitored by assessing the levels of hepatitis B virus deoxyribonucleic acid (HBV DNA), alanine aminotransferase (ALT), HBeAg, and anti-HBeAg seroconversion as well as by qualitative/ quantitative HBsAg serology during this period. After a 5 year follow-up,HBeAg loss was verified in the three HBeAg (+) patients, in two cases with seroconversion to anti-HBeAg. A reduction to undetectable viral load was observed in 5 out of 6 patients, and in two cases HBsAg seroconversion was also detected. ALT increases above the 2X upper limit of normal (ULN) were only detected in HBeAg (+) patients and associated with HBe antigen loss. All patients had stiffness levels below 7.8 KPa by Fibroscan assessment at the end of this period. Although only a few patients were enrolled in this study, it seems that HeberNasvac may maintain some of the therapeutic effects for a prolonged period. How to cite this article: Fernandez G, Sanchez AL, Jerez E, Anillo LE, Freyre F, Aguiar JA, Leon Y, Cinza Z, Diaz PA, Figueroa N, Muzio V, Nieto GG, Lobaina Y, Aguilar A, Penton E, Aguilar JC. Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac. Euroasian J Hepatogastroenterol, 2018;8(2):133-139.
format Online
Article
Text
id pubmed-6395482
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-63954822019-03-01 Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac Fernández, Guillermo L Sanchez, Ana Jerez, Everardo E Anillo, Luis Freyre, Freya A Aguiar, Jorge Leon, Yamila Cinza, Zurina A Diaz, Pablo Figueroa, Nelvis Muzio, Verena G Nieto, Gerardo Lobaina, Yadira Aguilar, Arístides Penton, Eduardo C Aguilar, Julio Euroasian J Hepatogastroenterol Research Article A novel therapeutic vaccine for chronic hepatitis B (CHB) treatment comprising the recombinant hepatitis B surface (HBsAg) and nucleocapsid (HBcAg) antigens has been developed. Preclinical and clinical trials (CT) evidenced safety and immunogenicity in animal models as well as in phases I, II, and III clinical trials. A phase I CT has conducted in Cuba in 6 CHB patients refractory or incomplete responders to α-IFN. Patients were immunized ten times every two weeks via. nasal spray, with 100 ug HBsAg and 100 ug HBcAg. Clinical efficacy was monitored by assessing the levels of hepatitis B virus deoxyribonucleic acid (HBV DNA), alanine aminotransferase (ALT), HBeAg, and anti-HBeAg seroconversion as well as by qualitative/ quantitative HBsAg serology during this period. After a 5 year follow-up,HBeAg loss was verified in the three HBeAg (+) patients, in two cases with seroconversion to anti-HBeAg. A reduction to undetectable viral load was observed in 5 out of 6 patients, and in two cases HBsAg seroconversion was also detected. ALT increases above the 2X upper limit of normal (ULN) were only detected in HBeAg (+) patients and associated with HBe antigen loss. All patients had stiffness levels below 7.8 KPa by Fibroscan assessment at the end of this period. Although only a few patients were enrolled in this study, it seems that HeberNasvac may maintain some of the therapeutic effects for a prolonged period. How to cite this article: Fernandez G, Sanchez AL, Jerez E, Anillo LE, Freyre F, Aguiar JA, Leon Y, Cinza Z, Diaz PA, Figueroa N, Muzio V, Nieto GG, Lobaina Y, Aguilar A, Penton E, Aguilar JC. Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac. Euroasian J Hepatogastroenterol, 2018;8(2):133-139. Jaypee Brothers Medical Publishers 2018 2019-02-01 /pmc/articles/PMC6395482/ /pubmed/30828555 http://dx.doi.org/10.5005/jp-journals-10018-1279 Text en Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Research Article
Fernández, Guillermo
L Sanchez, Ana
Jerez, Everardo
E Anillo, Luis
Freyre, Freya
A Aguiar, Jorge
Leon, Yamila
Cinza, Zurina
A Diaz, Pablo
Figueroa, Nelvis
Muzio, Verena
G Nieto, Gerardo
Lobaina, Yadira
Aguilar, Arístides
Penton, Eduardo
C Aguilar, Julio
Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title_full Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title_fullStr Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title_full_unstemmed Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title_short Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
title_sort five-year follow-up of chronic hepatitis b patients immunized by nasal route with the therapeutic vaccine hebernasvac
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395482/
https://www.ncbi.nlm.nih.gov/pubmed/30828555
http://dx.doi.org/10.5005/jp-journals-10018-1279
work_keys_str_mv AT fernandezguillermo fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT lsanchezana fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT jerezeverardo fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT eanilloluis fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT freyrefreya fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT aaguiarjorge fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT leonyamila fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT cinzazurina fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT adiazpablo fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT figueroanelvis fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT muzioverena fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT gnietogerardo fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT lobainayadira fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT aguilararistides fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT pentoneduardo fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac
AT caguilarjulio fiveyearfollowupofchronichepatitisbpatientsimmunizedbynasalroutewiththetherapeuticvaccinehebernasvac